Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Investing Activities (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Cash from Investing Activities data on record, last reported at -$339.4 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 439.49% year-over-year to -$339.4 million; the TTM value through Dec 2025 reached -$37.6 million, up 83.57%, while the annual FY2025 figure was -$37.6 million, 83.57% up from the prior year.
  • Cash from Investing Activities reached -$339.4 million in Q4 2025 per VRDN's latest filing, down from $126.1 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $126.1 million in Q3 2025 and bottomed at -$339.4 million in Q4 2025.
  • Average Cash from Investing Activities over 5 years is -$27.5 million, with a median of $7.6 million recorded in 2021.
  • Peak YoY movement for Cash from Investing Activities: soared 11894.34% in 2021, then plummeted 975.93% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$80.2 million in 2021, then tumbled by 125.16% to -$180.6 million in 2022, then rose by 6.03% to -$169.7 million in 2023, then soared by 62.93% to -$62.9 million in 2024, then crashed by 439.49% to -$339.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$339.4 million in Q4 2025, $126.1 million in Q3 2025, and $75.7 million in Q2 2025.